Bibliography
- Haylen BT, de Ridder D, Freeman RM, An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 2010;21(1):5-26
- Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life or urinary incontinent women. Br J Obstet Gnaecol 1997;10:1374-9
- Irwin DE, Milsom I, Hunsaakar S, Population- based survey of urinary incontinence, overactive bladder, and lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15
- Reeves P, Irwin D, Kelleher C, The current and future burden cost and cost of the overactive bladder in five European countries. Eur Urol 2006;50(5):1050-7
- National Institute for Health and Clinical Excellence(2006). Urinary incontinence: The Management of Urinary Incontinence in women. Available from: http:www.nice.org.uk/nicemedia/pdf/cg40NICEguidelinepdf
- Malhotra, Gandelman K, Sachse R, The design and development of fesoterodine as a prodrug of 5-hydroxymeythyl tolterodine (5-HMT)the active metabolite of toterodine. Curr Med Chem 2009;16:4481-9
- Tubaro A, d De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline. EAU Update series 2004;2:161
- Cole P. Fesoterodine an advanced antimuscarinic for the treatment of overactive bladder. A safety update. Drugs Future 2004;29:715
- Chapple C, Van Kerrebroeck P, Tubaro A, Clinical efficacy, safety, and tolerability of once-daily Fesoterodine in subjects with overactive Bladder. Eur Urol 2007;52(4):1204-12
- Nitti VW, Dmochowski R, Sand P, Efficacy, safety and tolerability of Fesoterodine for the overactive bladder syndrome. J Urol 2007;178:2488-94
- Herschorn S, Swift S, Guan Z, Comparison of fesoterodine and tolterodine extended release for the treatment of the overactive bladder: a head-to head placebo-controlled trial. BJU Int 2010;105(1):58-66
- Toviaz PR. Summary of product characteristics. Pfizer Ltd; 2007
- A Clinical Summary – Fesoterodine- Pfizer Ltd – December 2008
- Scarpero H, Sand P, Kelleher C, Long term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin 2011;27(5):921-30